Korean CRO CorestemChemon Expands into Cutting-Edge Preclinical Solutions

CorestemChemon, a Korean preclinical contract research organization (CRO), has announced a strategic partnership with ATG Lifetech to broaden its service offerings in the pharmaceutical industry. This collaboration aims to introduce next-generation nonclinical solutions, combining advanced technologies in organoids and transcriptomics to enhance drug development processes.

Partnership to Revolutionize Preclinical Testing

The alliance between CorestemChemon and ATG Lifetech will focus on developing a multi-faceted platform that integrates transcriptomics for predicting drug safety and efficacy. This innovative approach includes the creation of organoid models for critical organs such as the liver, heart, and blood-brain barrier. Additionally, the partnership will offer a transcriptomics analytics service designed to detect false positives in tumorigenicity studies.

A spokesperson for CorestemChemon emphasized the significance of this collaboration, stating, "ATG Lifetech's disruptive transcriptome and organoid platforms will significantly elevate the scientific fidelity of our preclinical services. This alliance positions us to compete as a global CRO partner offering best-in-class biological relevance and regulatory readiness."

Anticipated Launch and Market Demand

The combined expertise of both companies in FDA and European Medicines Agency regulations is expected to streamline the regulatory process for clients. CorestemChemon projects that this integrated approach will help pharmaceutical companies "de-risk clinical entry and reduce overall development timelines."

The partnership has set an ambitious timeline for the rollout of new services. Following presentations of their collaborative results at an upcoming toxicology and preclinical science conference later this year, the companies plan to launch global services. The CorestemChemon spokesperson revealed, "Revenue-generating service offerings are expected to begin rolling out by late 2025, with significant global demand already projected."

Expanding Beyond CRO Services

While this partnership marks a significant expansion of CorestemChemon's CRO capabilities, it's worth noting that the company's interests extend beyond contract research. CorestemChemon also maintains a biotech arm dedicated to the development of stem cell medicines, showcasing the company's diverse approach to pharmaceutical innovation.